The Effect of Daily Consumption of Eggs on Cognitive Function in the Elderly

Overview

Cognitive impairment is also a major risk factor for development of dementia later in life. Findings from our studies suggest that the carotenoids, lutein and zeaxanthin may be important in cognitive function in the elderly. The investigators have previously reported eggs to be a highly bioavailable source of lutein and zeaxanthin. Our study evaluates long-term egg intervention as a treatment strategy for age-related cognitive impairment which could possibly prevent the onset of dementia. The investigators have also shown that lutein supplementation significantly improved verbal fluency scores in healthy older women. Our studies have shown that egg interventions can significantly increase serum lutein concentrations in older adults. Based on the sum of our findings, the next logical step will be to investigate the ability of lutein and zeaxanthin contained in eggs to influence cognitive function in older adults. The investigators hypothesize that there will be a significant increase in cognitive function measures in older adults provided with meals containing 2 egg/day at the end of 6 months, while no significant improvements will be observed in older adults given daily meals containing egg substitute. The proposed study is designed as a randomized, placebo controlled trial that tests the effects of 6 month supplementation with 2 eggs/day on cognitive function in older adults. Secondary analyses will determine whether baseline MP density predicts relative effectiveness of the intervention on cognitive function. Secondary outcomes include plasma biomarkers of oxidative stress and inflammation.

Full Title of Study: “The Effect of Consumption of 2 Eggs or 4 oz of Egg Substitute Daily for 6 Months on Cognitive Function in Older Adults.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2015

Detailed Description

The study is designed as a placebo controlled trial that tests the effects of 6 month supplementation with 2 eggs or 4 ounces of egg substitute a day on cognitive function in older adults. Subjects will be randomly assigned to one of the two groups. Secondary analyses will determine whether baseline macular pigment density (a non invasive measure of lutein and zeaxanthin in neural tissue) or choline status predicts relative effectiveness of the intervention on cognitive function. Secondary outcomes include plasma biomarkers of oxidative stress and inflammation, choline bioavailability, and genetic variants related to endogenous choline production. Participants will be recruited from community-dwelling men and women aged > 50 yr, and potential participants will be screened to meet cognitive and functional criteria. Participants will be pre-screened by telephone; those who appear to meet criteria will undergo further screening. The study will include baseline (0 month), 3 and 6 month visits for study procedures, and monthly telephone calls. Given that there is a visible difference between the two interventions (eggs, egg substitute), a blinded study is not possible.

Interventions

  • Other: eggs or egg whites
    • 2 eggs/day or 4 oz egg whites/day for 6 months

Arms, Groups and Cohorts

  • Placebo Comparator: egg white (control)
    • egg whites, 4 ounces per day for six months
  • Experimental: eggs
    • eggs, 2 large per day for 6 months

Clinical Trial Outcome Measures

Primary Measures

  • cognition
    • Time Frame: 6 months
    • measures of attention, executive function, verbal fluency will be made using a sensitive computerized program

Secondary Measures

  • inflammation
    • Time Frame: 6 months
    • markers of inflammation will be made in plasma

Participating in This Clinical Trial

Inclusion Criteria

  • men and women age > 50 years – BMI 19-30 kg/m2 – lutein intake of < 3 mg/d – DHA (docosahexaehoic acid) intake < 250 mg/d (including supplements) – Mini mental state exam (MMSE) score > 24 (Appendix B) – macular pigment density < 0.5 at 0.5 degrees – Beck Depression Inventory < 20 – free of known disease; – BMI 19-29 kg/m2 – must be able to give written informed consent – have normal hematologic parameters – normal values of plasma albumin – normal values for liver and kidney function (Appendix A) – no use of carotenoid, n3 fatty acid, multivitamin/mineral, or choline supplements (> 3 months).

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Tufts University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Elizabeth J Johnson, PhD, Principal Investigator, Tufts University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.